RIVA-SILDENAFIL TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

SILDENAFIL (SILDENAFIL CITRATE)

Pieejams no:

LABORATOIRE RIVA INC.

ATĶ kods:

G04BE03

SNN (starptautisko nepatentēto nosaukumu):

SILDENAFIL

Deva:

100MG

Zāļu forma:

TABLET

Kompozīcija:

SILDENAFIL (SILDENAFIL CITRATE) 100MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

4/8/30

Receptes veids:

Prescription

Ārstniecības joma:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0136261003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2023-07-20

Produkta apraksts

_RIVA-SILDENAFIL - Product Monograph _
_Page 1 of 54_
PRODUCT MONOGRAPH
PR
RIVA-SILDENAFIL
Sildenafil Citrate Tablets
Tablets, 25 mg, 50 mg and 100 mg Sildenafil
(as Sildenafil citrate)
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control No.:
276533
DATE OF INITIAL APPROVAL:
April
22, 2016
DATE OF REVISION:
July 20, 2023
_RIVA-SILDENAFIL - Product Monograph _
_Page 2 of 54_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
......................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
.......................................................................